Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxabolone is a synthetic anabolic-androgenic steroid (AAS) of the nandrolone (19-nortestosterone) group. It was never marketed in its base form but can be formulated as the cipionate ester prodrug oxabolone cipionate, which has been used medically. Oxabolone acts primarily by binding to androgen receptors in target tissues such as muscle and bone, leading to increased protein synthesis and nitrogen retention. These effects result in muscle growth and enhanced recovery. Like other anabolic steroids, it is associated with both anabolic (muscle-building) and androgenic (masculinizing) effects. Oxabolone is on the World Anti-Doping Agency's list of prohibited substances due to its performance-enhancing properties[2][3][4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxabolone.